Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
83 hedge funds and large institutions have $140M invested in Aralez Pharmaceuticals Inc. in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 27 closing their positions.
30% more capital invested
Capital invested by funds: $107M → $140M (+$32.3M)
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less funds holding
Funds holding: 95 → 83 (-12)
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
52% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $2.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$2.86M |
| 2 |
TLCM
Tiger Legatus Capital Management
New York
|
+$2.1M |
| 3 |
CAD
Craig A. Drill
|
+$1.71M |
| 4 |
BC
Broadfin Capital
New York
|
+$1.37M |
| 5 |
D.E. Shaw & Co
New York
|
+$818K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$5.29M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.51M |
| 3 |
AC
Armistice Capital
New York
|
-$2.57M |
| 4 |
Renaissance Technologies
New York
|
-$1.78M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.71M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
101
Tradewinds Capital Management
Bellingham,
Washington
| – | -$7.75K | -1,700 | -100% |
|
|
JC
102
JBF Capital
Aspen,
Colorado
| – | -$4K | -1,076 | Closed |
|
|
BIT
103
BlackRock Institutional Trust
San Francisco,
California
| – | -$1K | -243 | Closed |
|
104
Walleye Trading
New York
| – | +$264 | +58 | New |
|
ARLZ Hedge Fund Activity: Q3 2016 in Review
83 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q3 2016, worth a combined $140M — up 30% from $107M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ARLZ and 15 opened new positions — a net loss of 12 holders — while 23 trimmed existing stakes and 26 added.
The largest buyer was Elk Creek Partners, adding an estimated $2.86M. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $5.29M sold.
- 83 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q3 2016, down from 95 in Q2 2016.
- Funds reported $140M of Aralez Pharmaceuticals Inc. stock for Q3 2016, up 30% quarter-over-quarter.
- 15 funds opened new Aralez Pharmaceuticals Inc. positions in Q3 2016 and 27 closed out, a net change of -12 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q3 2016 was Elk Creek Partners, an estimated $2.86M added.
- The largest Aralez Pharmaceuticals Inc. seller in Q3 2016 was Janus Henderson Investors US, an estimated $5.29M sold.
Based on aggregated 13F filings for Q3 2016.